Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2016-09-28 18:10:56
Reporting Period:
Filing Date:
Accepted Time:
2016-09-28 18:10:56
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1557746 Aclaris Therapeutics Inc. ACRS Pharmaceutical Preparations (2834) 460571712
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1654337 Kamil Ali-Jackson C/o Aclaris Therapeutics, Inc.
101 Lindenwood Drive, Suite 400
Malvern PA 19355
Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-09-28 1,841 $0.72 77,798 No 4 M Direct
Common Stock Disposition 2016-09-28 1,841 $24.66 75,957 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee StockOption (right to buy) Disposition 2016-09-26 1,841 $0.00 1,841 $0.72
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,176 2024-08-12 No 4 M Direct
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2016.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.31 to $24.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. 25% of the shares underlying this option, representing a right to purchase a total of 4,017 shares, vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the issuer as of the applicable vesting date.